Jefferies initiated coverage of Veeva Systems with a Buy rating and $265 price target. The analyst says Veeva is a best in class software developer, positioned in fast-growing biopharma markets. Clinical operations desperately needs tighter systems and data integration, playing to Veeva’s strengths, the analyst tells investors in a research note. The firm says biotech funding is lifting off the bottom, “alleviating a pressure” for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VEEV:
- Veeva price target raised to $230 from $220 at KeyBanc
- 2 Stocks to Beat the Market – October 2023
- Oppenheimer tech/software analysts hold an analyst/industry conference call
- Salesforce launch of Pharma CRM to elevate debate on Veeva, says Morgan Stanley
- Veeva price target raised to $250 from $227 at Barclays